Connect with us


The Anti-inflammatory drug may be effective in the treatment of rare and severe covid complications in children: Study



The Anti-inflammatory drug may be effective in the treatment of rare and severe covid complications in children: Study

The Anti-inflammatory drug may be effective in the treatment of rare and severe covid complications in children: a Study of 

LONDON: Corticosteroids are a class of drugs that reduce inflammation, may be an effective treatment for children who are developing a very rare but serious condition in which, after a COVID-19 infection, according to a new study. 

All of 614 children in the study, which was published in the New England Journal of Medicine on Wednesday, was developed severe disease after contracting COVID-19. 
The condition of the so-called multisystem inflammatory syndrome in children (MISS C), it is thought to affect one in 50,000 children have been infected with the SARS-CoV-2 virus. 

The disease usually occurs after two to four weeks after the infection. It affects children of all ages, but it most often occurs in older children and young adults. 
Researchers at the Imperial College in London, the united kingdom, said that a strain of disorders characterized by high fever, often accompanied by abdominal pain, vomiting, red eyes, and red skin rash. 


According to the scientists, most of the international reports point to a 2 to 4% mortality rate associated with the disease. 
An important issue is that some of the affected children have developed inflammation of the arteries that supply the heart, the blood by which it leads, ” she said. 

The study suggests that the steroid can be a less expensive and more cost-effective alternative to an immunoglobulin, ” said Elizabeth Whittaker, one of the co-authors of the study from the Imperial College in London. 
“Corticosteroids are inexpensive and widely available around the world, but immunoglobulin is expensive and scarce all over the world. This is a particular problem in many low-and middle-income countries, ” she added. 

The researchers examined two of the first treatment for this condition is: a kind of steroid, called corticosteroids, such as methylprednisolone, and in the treatment of antibody called immunoglobulin. 
The antibodies that have come from the blood of a human being, and it has been shown to reduce inflammation in the body. 
The study also compared with initial treatment with steroids, together with the immunoglobulin. 

In the course of the investigation, and hundreds of physicians all over the world, were taken from the results of the treatment of a patient in the database. 
All three treatments), immunoglobulins, immunoglobulin, in combination with a corticosteroid and corticosteroid therapy not only resulted in a faster reduction of the inflammatory process. 

The researchers found that there were no significant differences between the three treatments in the rate of recovery of renal organ function, or the development of organ failure. 
She noted that the number of deaths (2%) was too low, in order to compare the treatments, however, the death was recorded in the organ failure is a challenge, a valuation that does not reveal any significant differences among the three treatments. 
The analysis was restricted to 80% of children who met the World Health Organization’s criteria for the MASS, C. 


There was evidence of a lower incidence of organ failure and death within two days and in those who received steroids alone as the primary treatment, as compared with immunoglobulins alone. 
However, the authors stress that there is not enough data to determine that all three of the treatments were equivalent in the prevention of coronary artery aneurysms. 

She added that about six percent of the children in the study were taken in the coronary artery. 
“Our discovery that treatment with immunoglobulin, steroids, or a combination of the two drugs leads to a more rapid elimination of the infection, it will have a major impact on children’s doctors all over the world, in the treatment of this deadly disease,” said Professor Michael Levin, of the University of the Infectious Diseases Division, which is in the research. 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *